As its “Immune Cell Atlas” Gets Better, Immunai Announces a $215 Million Series B

As its "Immune Cell Atlas" Gets Better, Immunai Announces a $215 Million Series B

Immunai is funded well. By February 2021, the company that started creating an immune system atlas in 2018 had raised $80 million. The company announced a $215 million Series B.

Immunai is collecting clinical immunological data. It combines genetic information with epigenetic changes and proteomics to map the immune system. This round, led by Koch Disruptive Technologies, brings the company’s total funding to $295 million.

advertisement
Battle Approved Motors. Invest Today!!
advertisement
Get a $250 Amazon Gift Card. Apply Today!

About Editorial Staff

The Editorial Staff is a dedicated team of writers and editors who oversee the content of a leading news site. With a commitment to accuracy, quality, and unbiased reporting, they work tirelessly to deliver up-to-date news articles that inform and engage readers. From researching and writing compelling stories to meticulously editing and fact-checking, the Editorial Staff ensures the highest standards of journalism are upheld, providing readers with reliable and trustworthy information in an ever-changing news landscape.

See Articles by Editorial Staff | Website

Search